Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2025
Erindi/veggspjald / Talk/poster E1
Höfundar / Authors: Jenny Lorena Molina Estupiñan1,2, Poorya Foroutan Pajoohian1,2, Gabriel Kristian Pedersen3, Dennis Christensen3, Serena Marchi4, Emanuele Montomoli4,5, Stefanía P. Bjarnarson1,2 Ingileif Jónsdóttir1,2, Auður Anna Aradóttir Pind1,2
Starfsvettvangur / Affiliations: 1 Faculty of Medicine, School of Health Sciences, University of Iceland, Iceland 2 Department of Immunology, Landspitali, the National University Hospital of Iceland, Iceland 3 Statens Serum Institut, Copenhagen, Denmark 4 Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy 5 VisMederi srl, Siena, Italy.
Kynnir / Presenter: Jenny Lorena Molina Estupinan
Childhood vaccination is crucial for protection against infectious diseases, yet vaccine shortages during pandemics underscore the need for dose-sparing strategies. Adjuvants can enhance immune responses, reducing required antigen doses. Herin, we evaluated the dose-sparing effects of adjuvants CAF01, CAF08b, and alum on neonatal antibody (Ab) responses to an influenza hemagglutinin (HA) vaccine (H1N1, A/Michigan/45/2015) and assessed cross-protection against a related strain (H1N1, A/Wisconsin/588/2019). For this, neonatal mice were immunized once with full (4µg) or fractional doses (2, 1, 0.5, 0.1 µg) of HA vaccine, with or without adjuvant. Serum samples were collected bi-weekly to measure micro-neutralization (MN) and hemagglutination inhibition (HAI) titers. A full unadjuvanted HA dose elicited low MN titers, with only 38% seroprotection. In contrast, CAF08b achieved a remarkable 40-fold dose-sparing effect, reaching 100% seroprotection with just 1/8th of the HA dose. CAF01 showed a 2-fold effect, with 88% seroprotection at 1/4th of the dose. Alum provided no dose-sparing effect. Both CAF08b and CAF01 also induced high cross-reactive HAI titers against the heterologous strain, reaching seroprotection in 63% and 38% of mice, respectively, with 2µg of HA. In conclusion, CAF01 and CAF08b significantly enhanced protective humoral responses with substantial dose-sparing effects, highlighting their potential for pediatric vaccination during periods of limited vaccine supply.